Responsiveness of gait analysis parameters in a cohort of 71 CMT subjects

Detection of worsening in the slowly progressive Charcot-Marie-Tooth disease (CMT) is difficult. As previous clinical scales showed low responsiveness, novel outcome measures are under study, including innovative approaches such as quantitative muscle MRI and instrumented movement analysis. Since gait analysis proved able to reliably quantify CMT locomotor deficits, we aimed to explore whether it can be a sensitive-to-change outcome measure in CMT studies. Clinical and biomechanical evaluations were performed in 71 CMT subjects at baseline and after a mean (±sd) of 28.9 ± 9.5 months. Locomotor tasks included natural walking, ascending and descending steps. Instrumented analysis of such tasks provided indexes related to muscle strength (kinetic parameters) and joint movement (kinematic parameters). Parameter responsiveness was expressed as Standardized Response Mean (SRM). Considering the whole CMT group, several parameters showed moderate responsiveness; subgrouping subjects according to disease severity allowed reaching high responsiveness (SRM >0.80). CMT Examination Score showed moderate responsiveness (SRM 0.53) in the minimally affected group; kinematic parameters were more responsive in this group, whereas kinetic parameters in the most severely affected one. Biomechanical parameters can represent suitable outcome measures for CMT by showing moderate-to-high responsiveness. These data suggest that appropriate selection of patient population and outcome measures is crucial for clinical trials' design.

[1]  M P Kadaba,et al.  Measurement of lower extremity kinematics during level walking , 1990, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[2]  Maurizio Ferrarin,et al.  Changes of gait pattern in children with Charcot-Marie-Tooth disease type 1A: a 18 months follow-up study , 2013, Journal of NeuroEngineering and Rehabilitation.

[3]  Rory O'Sullivan,et al.  The characteristics of gait in Charcot-Marie-Tooth disease types I and II. , 2007, Gait & posture.

[4]  D. Pareyson,et al.  Psychometrics evaluation of Charcot‐Marie‐Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis , 2014, Journal of the peripheral nervous system : JPNS.

[5]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[6]  M Rabuffetti,et al.  Gait pattern classification in children with Charcot-Marie-Tooth disease type 1A. , 2012, Gait & posture.

[7]  J. McGinley,et al.  Gait in children and adolescents with Charcot‐Marie‐Tooth disease: a systematic review , 2016, Journal of the peripheral nervous system : JPNS.

[8]  Jun Yu Li,et al.  Reliability and validity of the CMT neuropathy score as a measure of disability , 2005, Neurology.

[9]  C. McDonald,et al.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases. , 2012, Physical medicine and rehabilitation clinics of North America.

[10]  R. Riener,et al.  Stair ascent and descent at different inclinations. , 2002, Gait & posture.

[11]  V. Scaioli,et al.  Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease , 2007, NeuroMolecular Medicine.

[12]  M. Mcdermott,et al.  Reliability of the CMT neuropathy score (second version) in Charcot‐Marie‐Tooth disease , 2011, Journal of the peripheral nervous system : JPNS.

[13]  D. Cornblath,et al.  Does ability to walk reflect general functionality in inflammatory neuropathies? , 2016, Journal of the peripheral nervous system : JPNS.

[14]  R. D. de Haan,et al.  The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. , 2009, Brain : a journal of neurology.

[15]  O. Combarros,et al.  The application of nerve conduction and clinical studies to genetic counseling in hereditary motor and sensory neuropathy type I , 1989, Muscle & nerve.

[16]  F. Muntoni,et al.  168th ENMC International Workshop: Outcome measures and clinical trials in Charcot–Marie–Tooth disease (CMT) , 2010, Neuromuscular Disorders.

[17]  Mariano Serrao,et al.  Foot drop and plantar flexion failure determine different gait strategies in Charcot-Marie-Tooth patients. , 2007, Clinical biomechanics.

[18]  M. Shy,et al.  Charcot‐marie‐tooth disease subtypes and genetic testing strategies , 2011, Annals of neurology.

[19]  M. Mcdermott,et al.  Neuropathy progression in Charcot-Marie-Tooth disease type 1A , 2008, Neurology.

[20]  M. Ferrarin,et al.  Reliability of instrumented movement analysis as outcome measure in Charcot–Marie–Tooth disease: Results from a multitask locomotor protocol , 2011, Gait & posture.

[21]  L. Padua,et al.  Efficacy of focal mechanic vibration treatment on balance in Charcot-Marie-Tooth 1A disease: a pilot study , 2016, Journal of Neurology.

[22]  D. Pareyson,et al.  Ascorbic acid for the treatment of Charcot-Marie-Tooth disease. , 2015, The Cochrane database of systematic reviews.

[23]  Davide Pareyson,et al.  Diagnosis, natural history, and management of Charcot–Marie–Tooth disease , 2009, The Lancet Neurology.

[24]  M. Shy,et al.  Determinants of reduced health-related quality of life in pediatric inherited neuropathies , 2010, Neurology.

[25]  A. Thompson,et al.  Effect sizes can be misleading: is it time to change the way we measure change? , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  O. Blin,et al.  Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial , 2009, The Lancet Neurology.

[27]  D. Herrmann,et al.  Quality-of-life in Charcot–Marie–Tooth disease: The patient’s perspective , 2014, Neuromuscular Disorders.

[28]  D. Gladman,et al.  Methods for assessing responsiveness: a critical review and recommendations. , 2000, Journal of clinical epidemiology.

[29]  C. Fornusek,et al.  Relationship between physical performance and quality of life in Charcot‐Marie‐Tooth disease: a pilot study , 2016, Journal of the peripheral nervous system : JPNS.

[30]  T. Yousry,et al.  MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study , 2016, The Lancet Neurology.

[31]  T. Beißbarth,et al.  Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients , 2014, Neuromuscular Disorders.

[32]  D. Radice,et al.  Responsiveness of clinical outcome measures in Charcot−Marie−Tooth disease , 2015, European journal of neurology.

[33]  R. Lewis,et al.  High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. , 2013, JAMA neurology.

[34]  H. Houlden,et al.  Charcot–Marie–Tooth disease: frequency of genetic subtypes and guidelines for genetic testing , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  D. Radice,et al.  Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial , 2011, The Lancet Neurology.

[36]  M. Ferrarin,et al.  Postural stabilization and balance assessment in Charcot–Marie–Tooth 1A subjects , 2014, Gait & posture.

[37]  Gyula Acsadi,et al.  A comprehensive evaluation of the variation in ankle function during gait in children and youth with Charcot-Marie-Tooth disease. , 2013, Gait & posture.

[38]  M. Ferrarin,et al.  The influence of somatosensory and muscular deficits on postural stabilization: Insights from an instrumented analysis of subjects affected by different types of Charcot–Marie–Tooth disease , 2015, Neuromuscular Disorders.